The chemical class known as RAB19 activators encompasses a diverse group of compounds that can influence the activity of the RAB19 protein, a member of the RAB family of small GTPases involved in vesicular trafficking and membrane dynamics. These activators can impact RAB19 by modulating the guanine nucleotide exchange factors (GEFs) that catalyze the exchange of GDP for GTP, locking RAB19 in its active GTP-bound state. Additionally, they can affect the GTPase-activating proteins (GAPs) that accelerate the hydrolysis of GTP to GDP, returning RAB19 to its inactive state. The function of RAB19 is also regulated by GDP dissociation inhibitors (GDIs), which sequester RAB19 in the cytosol and prevent its insertion into membranes. By influencing these regulatory proteins, RAB19 activators can alter the cycling of RAB19 between its active and inactive states and impact its role in intracellular trafficking processes.
These activators operate through various cellular mechanisms. Some are analogs of GTP that resist hydrolysis, therefore sustaining RAB19 in an active form. Others interfere with the structure and function of cellular organelles, such as the Golgi apparatus, which can lead to changes in membrane trafficking pathways that necessitate the activation of RAB19. There are also compounds that inhibit other small GTPases or their GEFs, which can result in cross-talk effects that indirectly initiate RAB19 activation due to the interconnected nature of cellular signaling pathways. Furthermore, some activators target proteins involved in the dynamics of the cytoskeleton or vesicle formation, leading to changes in cellular trafficking that can prompt the activation of RAB19 to facilitate these processes. Collectively, the actions of RAB19 activators are centered on modulating the molecular switches that govern RAB19's role in vesicular transport and membrane trafficking within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts Golgi structure and function, which can lead to altered RAB19 cycling and membrane trafficking. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
Inhibits Rac1, another Rho GTPase, potentially influencing RAB19 function through modulation of actin cytoskeleton dynamics. | ||||||
PAC 1 | 315183-21-2 | sc-203174 sc-203174A | 10 mg 50 mg | $132.00 $536.00 | 1 | |
Inhibits cytohesins, which are GEFs for ARF GTPases, potentially affecting ARF-RAB interactions and subsequent RAB19 activity. | ||||||
DBeQ | 177355-84-9 | sc-499943 | 10 mg | $330.00 | 1 | |
A selective ATP-competitive inhibitor of the AAA ATPase p97, which is involved in membrane fusion and can influence RAB19-mediated vesicle trafficking. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
An inhibitor of the Wiskott-Aldrich syndrome protein (WASP), which can impact actin polymerization and, subsequently, RAB19-associated vesicle movement. | ||||||
NVP-BHG712 | 940310-85-0 | sc-364554 sc-364554A | 5 mg 50 mg | $232.00 $1764.00 | ||
An inhibitor of formin-mediated actin assembly, which could impact cytoskeletal dynamics and thereby influence RAB19 function. | ||||||
(2S)-2-(4-Chlorophenyl)-1-[4-[(5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-1-piperazinyl]-3-[(1-methylethyl)amino]-1-propanone | sc-501166 | 5 mg | $540.00 | |||
An AKT inhibitor, which could affect RAB19 activity by altering signaling pathways that regulate vesicle trafficking. | ||||||